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Abstract
Despite the availability of several new agents for the treatment of rheumatoid arthritis (RA), sulfasalazine remains the mainstay 
because of both cost and experience with its use. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism 
and several polymorphisms have been described in the MTHFR gene. Of these, the 677C>T and 1298A>C polymorphisms have 
been associated with altered enzyme activity. To examine the association between 677C>T and 1298A>C MTHFR polymorphisms 
and sulfasalazine efficacy for the treatment of RA, a total of 117 RA patients treated with sulfasalazine (1 g daily; duration of 
treatment 17 ± 5 months) were analyzed. The 677C>T and 1298 A>C polymorphisms were detected using a PCR-RFLP method. 
RA was diagnosed according to the criteria of the American College of Rheumatology (ACR). The remission of RA symptoms 
was evaluated according to the ACR 20% response criteria. Allele and genotype frequencies were compared by the two-sided 
Fisher exact test. The frequency of remission was 47.2% and 44.6% in carriers of 677T and 1298C alleles, compared to 40.7% 
and 42.0% in carriers of 677C and 1298A alleles, respectively. These differences were statistically non-significant. When the 
multivariate analysis was additionally adjusted for patients’ age, gender and RA duration, the association of the MTHFR 677T 
allele with increased frequency of remission was statistically significant. Although RA remission rate in carriers of the MTHFR 
677T and 1298C alleles was more frequently observed, it does not seem that 677C>T and 1298A>C MTHFR polymorphisms 
have a major influence on treatment outcome in RA patients treated with sulfasalazine.
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1990’s, results in an alanine by valine substitution of a C by 
T at nucleotide 677 of the MTHFR enzyme. This leads to 
the thermolabile variant of MTHFR with decreased enzyme 
activity and subsequent increased plasma homocysteine 
levels (4). The homozygous 677T variant, with about 30% 
of wild-type activity, is present in about 8-10% of the Cau-
casian population. Heterozygotes have about 60% activity 
and form approximately 40% of the population (5). The 
677C>T polymorphism has been shown to be associated 
with a decreased risk for acute lymphoblastic leukemia (6) 
and colorectal neoplasia (7), and an increased risk for neural 
tube defects (8) and cardiovascular disease (5). It has also 
been shown to influence the clinical effects of drugs such 
Rheumatoid arthritis (RA) is a disease of complex 
pathogenesis and its treatment is mainly based on drugs 
modulating its course, e.g., methotrexate and sulfasalazine 
(1). It is well known that methotrexate inhibits dihydrofolate 
reductase (DHFR) and folate-dependent enzymes (2). 
Studies have shown that the anti-inflammatory action of 
sulfasalazine is also associated with inhibition of folate 
metabolism (3).
Several polymorphisms have been described in the 
methylenetetrahydrofolate reductase (MTHFR) gene. Of 
these, the 677C>T and 1298A>C polymorphisms have 
been associated with altered phenotypes and adverse drug 
events. The C677T polymorphism, first described in the mid 
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as anticonvulsants (9), levodopa (10), estrogens (11), and 
cholestyramine (12).
A second common polymorphism in the MTHFR gene is 
a 1298A>C transition that results in a glutamate to alanine 
substitution within a presumed regulatory domain of MTHFR. 
The 1298C allele has been reported to lead to decreased 
enzyme activity, although not to the same extent as the 
677T allele (8). 
The aim of the present study was to examine the effect of 
677C>T and 1298A>C MTHFR polymorphisms on treatment 
outcome in patients with RA treated with sulfasalazine.
Material and Methods
Patients
The study was approved by the local Ethics Commit-
tee and written informed consent was obtained from all 
subjects.
The study was carried out on 117 patients [92 women 
and 25 men aged 21-70 (61.0 ± 11.9) years, RA duration 
1-35 (10.3 ± 8.2) years] diagnosed with RA and treated with 
1 g sulfasalazine daily. RA was diagnosed according to the 
criteria of the American College of Rheumatology (ACR). All 
patients underwent a monthly evaluation for one year based 
on the 1995 ACR preliminary definition of improvement in 
RA (20% response criteria). The ACR core set of variables 
include: number of swollen joints, number of tender joints, 
physician’s global assessment of disease activity on a 0-10 
scale, patient’s global assessment of disease activity on 
a 0-10 scale, patient’s assessment of pain on a 100-mm 
visual analog scale, and functional status of the patient 
using the Health Assessment Questionnaire (HAQ) scored 
on a 0-3 scale. A 28-joint count (including the metacarpo-
phalangeal joints, the proximal interphalangeal joints, wrists 
and elbows) was used (13). A patient was classified as a 
good responder when both tender joint count and swollen 
joint count showed ≥20% improvement from baseline and 
at least 3 of the following criteria were met: ≥20% improve-
ment in visual analog scale, in erythrocyte sedimentation 
rate, in physician’s global assessment of disease activity, 
in patient’s global assessment of disease activity, and in 
HAQ. The “good responders” group included patients in 
remission for at least 6 months (14,15).
Genotyping
Genomic DNA was extracted manually by precipitation 
with trimethylammonium bromide salts from leukocytes 
contained in 450 μL of venous blood collected with ethyl-
enediaminetetraacetic acid as an anticoagulant. DNA was 
then precipitated in 95% ethanol, dissolved in distilled water 
and stored at -20°C until analysis. The 677C>T and 1298 
A>C polymorphisms were detected using a PCR-RFLP 
method as previously described (16).
Statistical analysis
Allele and genotype frequencies were compared by 
the two-sided Fisher exact test. Odds ratios (OR) and their 
95% confidence intervals (95%CI) were calculated for the 
chance to respond to sulfasalazine treatment.
Univariate and multivariate logistic regression models 
were used to analyze the influence of 677C>T and 1298A>C 
polymorphisms on sulfasalazine treatment response. The 
independent variables in these models were numbers of 
677T and 1298C alleles (0, 1, or 2) or haplotypes for each 
patient. A multivariate model additionally adjusted for pa-
tients’ age, gender and RA duration was also analyzed.
A P value level of less than 0.05 was considered sta-
tistically significant. Calculations were performed using the 
Statistica 6.1 software package (USA).
Results
The clinical features of the patients before treatment are 
presented in Table 1.
Distribution of both MTHFR genotypes was consistent 
with Hardy-Weinberg equilibrium (P > 0.40). The efficacy 
of RA therapy with sulfasalazine is presented in Table 2. 
Under sulfasalazine therapy, remission of RA symptoms was 
achieved in 9 of 11 MTHFR 677TT genotype carriers, in 33 
of 50 subjects with the 677CT genotype, and in 33 of 56 
patients with the 677CC genotype. The frequency of the T 
allele among sulfasalazine responders was not statistically 
different from the group of poor responders (OR = 1.55, 
95%CI = 0.85-2.81, P = 0.184).
The remission of RA symptoms was observed in 5 of 
7 MTHFR 1298CC genotype carriers, in 34 of 51 subjects 
with the 1298AC genotype, and in 36 of 59 patients with 
the 1298AA genotype. The frequency of the C allele among 
sulfasalazine responders was 29%, compared to 25% for a 
Table 1. Clinical features of 117 patients with rheumatoid arthritis 
before treatment.
Parameter
Erythrocyte sedimentation rate (mm/h) 47.65 ± 21.24
Swollen joints (N) 6.32 ± 2.12
Tender joints (N) 7.75 ± 2.78
Visual analog scale (mm) 52.6 ± 17.1
C-reactive protein (mg/dL) 35.48 ± 25.42
Disease duration (years) 10.3 ± 8.2 
Data are reported as mean ± SD.
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group of poor sulfasalazine responders (OR = 1.25, 95%CI 
= 0.68-2.28, P = 0.544). 
Univariate regression analysis revealed that the MTHFR 
677T allele was associated with a 1.5-fold higher frequency 
of remission. In the multivariate regression analysis, taking 
into account the combined effect of the MTHFR 677T and 
1298C alleles, the numbers of both alleles appeared to be 
associated with increased frequency of remission, but this as-
sociation was not statistically significant (Table 3). However, 
when the multivariate analysis was additionally adjusted for 
patient age, gender and RA duration, the association of the 
MTHFR 677T allele with increased frequency of remission 
became statistically significant (Table 3).
In the haplotype analysis, three of four theoretically 
possible haplotypes of two loci were found in our patients 
(Table 4). The higher number of 677C-1298A haplotypes was 
associated with a decreased frequency of remission (OR = 
0.56, 95%CI = 0.31-0.99, P = 0.046). This association was 
even more significant when the logistic regression model 
was adjusted for patient age, gender and RA duration (OR 
= 0.50, 95%CI = 0.27-0.92, P = 0.025).
Discussion
Although sulfasalazine has been used for many years in 
the management of patients with RA, its mechanism of action 
is not known. With respect to its potential immunomodulatory 
effects, several in vitro studies have shown that sulfasalazine 
and its metabolites inhibit the release of cytokines produced 
by various cell types. Among the cytokines affected by sul-
fasalazine are T-cell cytokines such as interleukin 2 (IL-2) 
(17) and those produced by monocytes or macrophages, 
including IL-1, IL-6, IL-12 (17-19) and tumor necrosis factor 
alpha (TNF-α) (17). How sulfasalazine inhibits the release 
of cytokines has not been fully elucidated. Some stud-
ies have shown, for example, that sulfasalazine inhibits 
TNF-α expression in macrophages by inducing apoptosis 
(20). Cytokines mediate and regulate a number of cellular 
responses, including T-cell proliferation, natural killer cell 
activity and activation of B cells. Sulfasalazine and, to a 
lesser extent, its metabolites sulfapyridine and mesalazine 
have been shown to inhibit these cellular responses in a 
number of different systems in vitro (21). 
Previous studies have suggested that sulfasalazine also 
has antifolate properties (3). Sulfasalazine was found to 
influence folate concentrations, possibly by interfering with 
folate absorption. The influence of sulfasalazine on serum 
folic acid concentrations in RA patients has been disputed. 
A direct influence on folate metabolism in vivo has not been 
investigated and the influence of folates on the clinical 
impact of sulfasalazine has never been studied. 
Table 2. 677C>T and 1298A>C genotypes and rheumatoid arthri-







TT 9 (12%) 2 (5%) 3.14 (0.62-15.88)
CT 33 (44%) 17 (40%) 1.35 (0.61-2.98)
CC 33 (44%) 23 (55%) -
677C>T allele
T 51 (34%) 21 (25%) 1.55 (0.85-2.81)
C 99 (66%) 63 (75%) -
1298A>C genotype
CC 5 (7%) 2 (5%) 1.60 (0.29-8.93)
AC 34 (45%) 17 (40%) 1.28 (0.58-2.80)
AA 36 (48%) 23 (55%) -
1298A>C allele
C 44 (29%) 21 (25%) 1.25 (0.68-2.28)
A 106 (71%) 63 (75%) -
Data are reported as number and percent. P > 0.05 when the 
numbers of homozygotes 677TT or 1298CC and 677CT or 
1298AC heterozygotes were compared with homozygotes, 
677CC or 1298AA, by the Fisher exact test.
Table 3. Univariate and multivariate logistic regression models 
predicting odds ratios for patients’ response to treatment in rela-
tion to 677C>T and 1298A>C genotypes.
Logistic regression model OR (95%CI)
Number of 677T 
alleles
Number of 1298C 
alleles
Univariate 1.55 (0.84-2.87) 1.27 (0.67-2.42)
Multivariate (677T + 1298C) 1.89 (0.96-3.69) 1.67 (0.82-3.39)
Multivariate (677T + 1298C    
+ age + gender + RA 
duration)
2.28 (1.09-4.79)* 1.76 (0.84-3.66)
Odds ratios calculated for presence of one copy of the indicated 
allele. RA = rheumatoid arthritis. *P = 0.027.
Table 4. Univariate logistic regression models predicting odds 
ratios for patients’ response to treatment in relation to 677-1298 
haplotypes.
Haplotype OR (95%CI) for positive response
677C-1298A 0.56 (0.31-0.99)* 
677C-1298C 1.27 (0.67-2.42)
677T-1298A 1.55 (0.84-2.87)
Odds ratios calculated for presence of one copy of the indicated 
haplotype. *P < 0.05.
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In the present study, we examined the effect of 677C>T 
and 1298A>C MTHFR polymorphisms on the treatment 
outcome of RA patients treated with sulfasalazine. In the 
genotype analysis, there was no statistically significant 
association of the genotypes studied with response to 
treatment. In the multivariate analysis additionally adjusted 
for patient age, gender and RA duration, the MTHFR 677T 
allele was significantly associated with increased frequency 
of remission.
The increased frequency of remission of RA symptoms 
in patients treated with sulfasalazine carrying the MTHFR 
677T allele, which is associated with lower MTHFR activ-
ity, suggests that decreased MTHFR expression might be 
associated with a better response to treatment. This effect 
may involve more efficient down-regulation of 5-methyl-THF 
synthesis through MTHFR, and subsequently reduced me-
thionine production from homocysteine and 5-methyl-THF 
through methionine synthase and S-adenosylmethionine. 
S-adenosylmethionine is the main donor of a methyl group in 
several biochemical pathways and reactions of DNA methy-
lation (22). A limited availability of S-adenosylmethionine 
may affect the expression of genes involved in the inflam-
matory response in RA patients.
Moreover, MTHFR polymorphism may influence plasma 
homocysteine concentrations in RA patients treated with 
methotrexate and sulfasalazine. Haagsma et al. (3) showed 
that the patients homozygous for the MTHFR gene mutation 
C677T had significantly higher baseline homocysteine, and 
that the heterozygous individuals presented significantly 
higher plasma homocysteine after therapy. No correlation 
was found between clinical efficacy variables and ho-
mocysteine. Patients with gastrointestinal toxicity had a 
significantly higher increase in homocysteine. A persistent 
increase in plasma homocysteine concentrations was ob-
served in patients treated with methotrexate alone and more 
pronounced in combination with sulfasalazine, in contrast 
with sulfasalazine alone. 
The results cited above indirectly suggest that the anti-
inflammatory action of sulfasalazine in patients with RA 
might also be associated with influence on folate and purine 
synthesis in cells involved in the inflammatory response. 
Nevertheless, this hypothesis requires further investigation. 
Although RA remission was observed more frequently in 
carriers of the MTHFR 677T and 1298C alleles, it does not 
seem that 677C>T and 1298A>C MTHFR polymorphisms 
have a significant influence on treatment outcome in RA 
patients treated with sulfasalazine. 
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